Form 4: United Therapeutics' President and COO, Michael Benkowitz, Executes Stock Options and Sells Shares Under 10b5-1 Plan

Michael Benkowitz, President and COO of United Therapeutics, exercised stock options and sold shares of common stock on February 3, 2025, according to a pre-arranged Rule 10b5-1 trading plan.

Summary

• On February 3, 2025, Michael Benkowitz, the President and COO of United Therapeutics, executed stock options and sold shares of the company's common stock.
• These transactions were conducted under a pre-existing Rule 10b5-1 trading plan established on August 7, 2024.
• The sales were executed in multiple trades at varying prices, with weighted average prices reported for each transaction.
• The shares are held in trusts beneficially owned by Benkowitz and his family members.
• Benkowitz exercised options to acquire 10,000 shares at a price of $111.
• He then sold 7,500 shares held in one trust and 2,500 shares held in another trust.
• Following these transactions, Benkowitz directly owns 2,577 shares and indirectly owns shares through trusts.
• He indirectly owns 29,679 options through one trust and 12,000 options through another trust.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the document simply reports transactions executed under a pre-existing plan. It doesn't provide any indication of management's outlook or company performance.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions. It is common for executives to utilize Rule 10b5-1 trading plans to sell shares over time to avoid accusations of insider trading. The filing itself doesn't necessarily indicate a positive or negative outlook for the company.

Comparison to Industry Standards

• Executive compensation packages often include stock options as a form of long-term incentive.
• Rule 10b5-1 plans are a standard practice among corporate executives to manage their stock holdings and avoid potential insider trading concerns.
• The size and frequency of these transactions are typical for executives at publicly traded companies like United Therapeutics, when compared to similar companies such as Vertex Pharmaceuticals, Gilead Sciences, and Amgen.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership.
• The impact on employees, customers, suppliers, and creditors is likely negligible.

Key Dates